Comparison of two oestrogen receptor assays in the prediction of the clinical course of patients with advanced breast cancer
We have examined two new oestrogen receptor (ER) assays--an enzyme immunoassay (EIA) and an immunocytochemical assay (ICA) in a large series of primary breast tumours to compare their potential as predictors of (1) response to endocrine therapy and (2) survival in patients developing advanced breast...
Gespeichert in:
| Veröffentlicht in: | British journal of cancer 1992-05, Vol.65 (5), p.727-730 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 730 |
|---|---|
| container_issue | 5 |
| container_start_page | 727 |
| container_title | British journal of cancer |
| container_volume | 65 |
| creator | ROBERTSON, J. F. R BATES, K PEARSON, D BLAMEY, R. W NICHOLSON, R. I |
| description | We have examined two new oestrogen receptor (ER) assays--an enzyme immunoassay (EIA) and an immunocytochemical assay (ICA) in a large series of primary breast tumours to compare their potential as predictors of (1) response to endocrine therapy and (2) survival in patients developing advanced breast cancer. Response to endocrine therapy was categorised at 6 months (UICC criteria). ER-ICA appears the better predictor of response to endocrine therapy than ER-EIA. Combining ICA and EIA results did not improve the prediction of response. With both assays patients with ER positive tumours survived longer from the time of diagnosis of advanced disease than those with ER negative tumours. The predictive power of these assay for progression of disease appears slightly better for the ER-ICA. |
| doi_str_mv | 10.1038/bjc.1992.153 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1977381</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72945036</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3483-2432a43b430de4916fdc07853f2b371535770e55104d9f8c49f747b3f34bce813</originalsourceid><addsrcrecordid>eNpVkU1v1DAQhi0EKtvCjSuSD4gTWfy5ji9IaAUFqRKXcrYcZ9x1lY2D7bSqxI-v010t5WJr5n0873gGoXeUrCnh7efu1q2p1mxNJX-BVvVkDW2ZeolWhBDVEM3Ia3Se820NNWnVGTqrkCBUr9DfbdxPNoUcRxw9LvcRR8glxRsYcQIHU4kJ25ztQ8ZhxGUHeErQB1fC8UnNuCGMwdkBuzinDEt6siXAWDK-D2WHbX9nRwc97hLYXLBbovQGvfJ2yPD2eF-g39-_XW9_NFe_Ln9uv141jouWN0xwZgXvBCc9CE03vndEtZJ71nFVvyKVIiAlJaLXvnVCeyVUxz0XnYOW8gv05VB3mrs99K72lexgphT2Nj2YaIP5XxnDztzEO0O1UvypwMdjgRT_zHU-Zh-yg2GwI8Q5G8W0kIRvKvjpALoUc07gTyaUmGVbpm7LLNsyte-Kv3_e2D_4sJ6qfzjqNtfx-lTHFvIJk0zKjSIVwwdstGVOcNKr12K1OD0CO6eqPQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72945036</pqid></control><display><type>article</type><title>Comparison of two oestrogen receptor assays in the prediction of the clinical course of patients with advanced breast cancer</title><source>MEDLINE</source><source>Nature Journals Online</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>SpringerLink Journals - AutoHoldings</source><creator>ROBERTSON, J. F. R ; BATES, K ; PEARSON, D ; BLAMEY, R. W ; NICHOLSON, R. I</creator><creatorcontrib>ROBERTSON, J. F. R ; BATES, K ; PEARSON, D ; BLAMEY, R. W ; NICHOLSON, R. I</creatorcontrib><description>We have examined two new oestrogen receptor (ER) assays--an enzyme immunoassay (EIA) and an immunocytochemical assay (ICA) in a large series of primary breast tumours to compare their potential as predictors of (1) response to endocrine therapy and (2) survival in patients developing advanced breast cancer. Response to endocrine therapy was categorised at 6 months (UICC criteria). ER-ICA appears the better predictor of response to endocrine therapy than ER-EIA. Combining ICA and EIA results did not improve the prediction of response. With both assays patients with ER positive tumours survived longer from the time of diagnosis of advanced disease than those with ER negative tumours. The predictive power of these assay for progression of disease appears slightly better for the ER-ICA.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/bjc.1992.153</identifier><identifier>PMID: 1534019</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>Basingstoke: Nature Publishing Group</publisher><subject>Aged ; Aging - metabolism ; Biological and medical sciences ; Breast Neoplasms - drug therapy ; Breast Neoplasms - metabolism ; Breast Neoplasms - ultrastructure ; Buserelin - analogs & derivatives ; Buserelin - therapeutic use ; Female ; Genital system. Mammary gland ; Goserelin ; Humans ; Immunoenzyme Techniques ; Immunohistochemistry ; Investigative techniques, diagnostic techniques (general aspects) ; Medical sciences ; Megestrol - analogs & derivatives ; Megestrol - therapeutic use ; Megestrol Acetate ; Menopause - metabolism ; Menopause - physiology ; Middle Aged ; Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques ; Predictive Value of Tests ; Prognosis ; Receptors, Estrogen - analysis ; Receptors, Estrogen - metabolism ; Sensitivity and Specificity ; Tamoxifen - therapeutic use</subject><ispartof>British journal of cancer, 1992-05, Vol.65 (5), p.727-730</ispartof><rights>1992 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3483-2432a43b430de4916fdc07853f2b371535770e55104d9f8c49f747b3f34bce813</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977381/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977381/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,2727,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=5255670$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1534019$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>ROBERTSON, J. F. R</creatorcontrib><creatorcontrib>BATES, K</creatorcontrib><creatorcontrib>PEARSON, D</creatorcontrib><creatorcontrib>BLAMEY, R. W</creatorcontrib><creatorcontrib>NICHOLSON, R. I</creatorcontrib><title>Comparison of two oestrogen receptor assays in the prediction of the clinical course of patients with advanced breast cancer</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><description>We have examined two new oestrogen receptor (ER) assays--an enzyme immunoassay (EIA) and an immunocytochemical assay (ICA) in a large series of primary breast tumours to compare their potential as predictors of (1) response to endocrine therapy and (2) survival in patients developing advanced breast cancer. Response to endocrine therapy was categorised at 6 months (UICC criteria). ER-ICA appears the better predictor of response to endocrine therapy than ER-EIA. Combining ICA and EIA results did not improve the prediction of response. With both assays patients with ER positive tumours survived longer from the time of diagnosis of advanced disease than those with ER negative tumours. The predictive power of these assay for progression of disease appears slightly better for the ER-ICA.</description><subject>Aged</subject><subject>Aging - metabolism</subject><subject>Biological and medical sciences</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - metabolism</subject><subject>Breast Neoplasms - ultrastructure</subject><subject>Buserelin - analogs & derivatives</subject><subject>Buserelin - therapeutic use</subject><subject>Female</subject><subject>Genital system. Mammary gland</subject><subject>Goserelin</subject><subject>Humans</subject><subject>Immunoenzyme Techniques</subject><subject>Immunohistochemistry</subject><subject>Investigative techniques, diagnostic techniques (general aspects)</subject><subject>Medical sciences</subject><subject>Megestrol - analogs & derivatives</subject><subject>Megestrol - therapeutic use</subject><subject>Megestrol Acetate</subject><subject>Menopause - metabolism</subject><subject>Menopause - physiology</subject><subject>Middle Aged</subject><subject>Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques</subject><subject>Predictive Value of Tests</subject><subject>Prognosis</subject><subject>Receptors, Estrogen - analysis</subject><subject>Receptors, Estrogen - metabolism</subject><subject>Sensitivity and Specificity</subject><subject>Tamoxifen - therapeutic use</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkU1v1DAQhi0EKtvCjSuSD4gTWfy5ji9IaAUFqRKXcrYcZ9x1lY2D7bSqxI-v010t5WJr5n0873gGoXeUrCnh7efu1q2p1mxNJX-BVvVkDW2ZeolWhBDVEM3Ia3Se820NNWnVGTqrkCBUr9DfbdxPNoUcRxw9LvcRR8glxRsYcQIHU4kJ25ztQ8ZhxGUHeErQB1fC8UnNuCGMwdkBuzinDEt6siXAWDK-D2WHbX9nRwc97hLYXLBbovQGvfJ2yPD2eF-g39-_XW9_NFe_Ln9uv141jouWN0xwZgXvBCc9CE03vndEtZJ71nFVvyKVIiAlJaLXvnVCeyVUxz0XnYOW8gv05VB3mrs99K72lexgphT2Nj2YaIP5XxnDztzEO0O1UvypwMdjgRT_zHU-Zh-yg2GwI8Q5G8W0kIRvKvjpALoUc07gTyaUmGVbpm7LLNsyte-Kv3_e2D_4sJ6qfzjqNtfx-lTHFvIJk0zKjSIVwwdstGVOcNKr12K1OD0CO6eqPQ</recordid><startdate>19920501</startdate><enddate>19920501</enddate><creator>ROBERTSON, J. F. R</creator><creator>BATES, K</creator><creator>PEARSON, D</creator><creator>BLAMEY, R. W</creator><creator>NICHOLSON, R. I</creator><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>19920501</creationdate><title>Comparison of two oestrogen receptor assays in the prediction of the clinical course of patients with advanced breast cancer</title><author>ROBERTSON, J. F. R ; BATES, K ; PEARSON, D ; BLAMEY, R. W ; NICHOLSON, R. I</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3483-2432a43b430de4916fdc07853f2b371535770e55104d9f8c49f747b3f34bce813</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Aged</topic><topic>Aging - metabolism</topic><topic>Biological and medical sciences</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - metabolism</topic><topic>Breast Neoplasms - ultrastructure</topic><topic>Buserelin - analogs & derivatives</topic><topic>Buserelin - therapeutic use</topic><topic>Female</topic><topic>Genital system. Mammary gland</topic><topic>Goserelin</topic><topic>Humans</topic><topic>Immunoenzyme Techniques</topic><topic>Immunohistochemistry</topic><topic>Investigative techniques, diagnostic techniques (general aspects)</topic><topic>Medical sciences</topic><topic>Megestrol - analogs & derivatives</topic><topic>Megestrol - therapeutic use</topic><topic>Megestrol Acetate</topic><topic>Menopause - metabolism</topic><topic>Menopause - physiology</topic><topic>Middle Aged</topic><topic>Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques</topic><topic>Predictive Value of Tests</topic><topic>Prognosis</topic><topic>Receptors, Estrogen - analysis</topic><topic>Receptors, Estrogen - metabolism</topic><topic>Sensitivity and Specificity</topic><topic>Tamoxifen - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>ROBERTSON, J. F. R</creatorcontrib><creatorcontrib>BATES, K</creatorcontrib><creatorcontrib>PEARSON, D</creatorcontrib><creatorcontrib>BLAMEY, R. W</creatorcontrib><creatorcontrib>NICHOLSON, R. I</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>ROBERTSON, J. F. R</au><au>BATES, K</au><au>PEARSON, D</au><au>BLAMEY, R. W</au><au>NICHOLSON, R. I</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of two oestrogen receptor assays in the prediction of the clinical course of patients with advanced breast cancer</atitle><jtitle>British journal of cancer</jtitle><addtitle>Br J Cancer</addtitle><date>1992-05-01</date><risdate>1992</risdate><volume>65</volume><issue>5</issue><spage>727</spage><epage>730</epage><pages>727-730</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>We have examined two new oestrogen receptor (ER) assays--an enzyme immunoassay (EIA) and an immunocytochemical assay (ICA) in a large series of primary breast tumours to compare their potential as predictors of (1) response to endocrine therapy and (2) survival in patients developing advanced breast cancer. Response to endocrine therapy was categorised at 6 months (UICC criteria). ER-ICA appears the better predictor of response to endocrine therapy than ER-EIA. Combining ICA and EIA results did not improve the prediction of response. With both assays patients with ER positive tumours survived longer from the time of diagnosis of advanced disease than those with ER negative tumours. The predictive power of these assay for progression of disease appears slightly better for the ER-ICA.</abstract><cop>Basingstoke</cop><pub>Nature Publishing Group</pub><pmid>1534019</pmid><doi>10.1038/bjc.1992.153</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 1992-05, Vol.65 (5), p.727-730 |
| issn | 0007-0920 1532-1827 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1977381 |
| source | MEDLINE; Nature Journals Online; EZB-FREE-00999 freely available EZB journals; PubMed Central; SpringerLink Journals - AutoHoldings |
| subjects | Aged Aging - metabolism Biological and medical sciences Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Breast Neoplasms - ultrastructure Buserelin - analogs & derivatives Buserelin - therapeutic use Female Genital system. Mammary gland Goserelin Humans Immunoenzyme Techniques Immunohistochemistry Investigative techniques, diagnostic techniques (general aspects) Medical sciences Megestrol - analogs & derivatives Megestrol - therapeutic use Megestrol Acetate Menopause - metabolism Menopause - physiology Middle Aged Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques Predictive Value of Tests Prognosis Receptors, Estrogen - analysis Receptors, Estrogen - metabolism Sensitivity and Specificity Tamoxifen - therapeutic use |
| title | Comparison of two oestrogen receptor assays in the prediction of the clinical course of patients with advanced breast cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T20%3A14%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20two%20oestrogen%20receptor%20assays%20in%20the%20prediction%20of%20the%20clinical%20course%20of%20patients%20with%20advanced%20breast%20cancer&rft.jtitle=British%20journal%20of%20cancer&rft.au=ROBERTSON,%20J.%20F.%20R&rft.date=1992-05-01&rft.volume=65&rft.issue=5&rft.spage=727&rft.epage=730&rft.pages=727-730&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/bjc.1992.153&rft_dat=%3Cproquest_pubme%3E72945036%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72945036&rft_id=info:pmid/1534019&rfr_iscdi=true |